Clinical Trials Sponsored by Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical Research & Development L

Total 19 results

Bayer
Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical...

Recruiting

An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism

Venous Thromboembolism

Japan
Johnson & Johnson Pharmaceutical Research & Development...
Janssen Pharmaceutica N.V., Belgium

Completed

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Pharmacokinetics | Advanced Malignancies | Solid Malignancies | Protein Kinase Inhibitors | Maximum Tolerated Dose | Antineoplastic Protocols | Clinical Trial, Phase 1
Johnson & Johnson Pharmaceutical Research & Development...
Janssen Pharmaceutica N.V., Belgium

Completed

A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.

Neoplasms | Lymphoma

United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Schizoaffective Disorder | Psychotic Disorder
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.

Anxiety Disorders
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States, India, Romania
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients

Bipolar Disorder
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.

Bipolar Disorder
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

Major Depressive Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Schizoaffective Disorder | Psychotic Disorder

United States, India, Malaysia, Romania, Korea, Republic of, Philippines
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection

Psychotic Disorders | Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression

Depressive Disorder | Depression | Depressive Disorder, Major
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development...
Janssen-Cilag Ltd.

Completed

A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies.

Neoplasms
Janssen-Ortho LLC
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine

Migraine | Common Migraine | Classic Migraine
Johnson & Johnson Pharmaceutical Research & Development...
Janssen-Cilag International NV

Completed

Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure (PRIMS)

Chronic Kidney Failure | Pure Red-Cell Aplasia

Poland, United Kingdom, Belgium, Germany, Spain, Portugal, Australia, Switzerland, Finland, Greece, Sweden, Netherlands, Norway, Ireland, Denmark
Johnson & Johnson Pharmaceutical Research & Development...
Janssen-Cilag International NV

Completed

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

Schizophrenia

United States, Ukraine, Romania, South Africa, Taiwan, Korea, Republic of, Russian Federation, Costa Rica, Mexico

Clinical Trials Sponsored by Janssen Pharmaceutical Companies (formerly Johnson & Johnson Pharmaceutical Research & Development L

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations